ulifloxacin has been researched along with clavulanic acid in 1 studies
| Studies (ulifloxacin) | Trials (ulifloxacin) | Recent Studies (post-2010) (ulifloxacin) | Studies (clavulanic acid) | Trials (clavulanic acid) | Recent Studies (post-2010) (clavulanic acid) |
|---|---|---|---|---|---|
| 50 | 3 | 15 | 1,801 | 212 | 424 |
| Protein | Taxonomy | ulifloxacin (IC50) | clavulanic acid (IC50) |
|---|---|---|---|
| Beta-lactamase | Klebsiella pneumoniae | 1.72 | |
| Beta-lactamase | Escherichia coli | 0.07 | |
| Beta-lactamase | Citrobacter gillenii | 0.009 | |
| Beta-lactamase | Shouchella clausii | 0.085 | |
| Beta-lactamase | Pseudomonas aeruginosa | 0.1 | |
| Beta-lactamase | Pseudomonas aeruginosa | 0.1 | |
| Beta-lactamase | Staphylococcus aureus | 0.08 | |
| Beta-lactamase | Escherichia coli K-12 | 0.015 | |
| Beta-lactamase SHV-1 | Escherichia coli | 0.028 | |
| Beta-lactamase SHV-1 | Klebsiella pneumoniae | 0.17 | |
| Beta-lactamase OXA-1 | Escherichia coli | 3.2 | |
| Cytochrome P450 2B6 | Homo sapiens (human) | 0.17 | |
| Beta-lactamase | Pseudomonas aeruginosa PAO1 | 0.8 | |
| Beta-lactamase TEM | Escherichia coli | 0.0933 | |
| Beta-lactamase | Salmonella enterica subsp. enterica serovar Westhampton | 0.01 | |
| Beta-lactamase | Pseudomonas aeruginosa | 0.1 | |
| Beta-lactamase | Klebsiella pneumoniae | 0.02 | |
| Class D beta-lactamase | Brachyspira pilosicoli | 2 | |
| Beta-lactamase | Pseudomonas luteola | 0.036 | |
| Beta-lactamase | Escherichia coli | 8.6 | |
| Beta-lactamase | Escherichia coli | 0.009 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keam, SJ; Perry, CM | 1 |
1 trial(s) available for ulifloxacin and clavulanic acid
| Article | Year |
|---|---|
Prulifloxacin.
Topics: Administration, Oral; Amoxicillin; Animals; Anti-Bacterial Agents; Bronchitis, Chronic; Ciprofloxacin; Clavulanic Acid; Dioxolanes; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Half-Life; Humans; Italy; Molecular Structure; New Zealand; Pefloxacin; Piperazines; Prodrugs; Quinolones; Urinary Tract Infections | 2004 |